Shares of Traws Pharma (NASDAQ:TRAW) shot up 24% in post-market trading Friday on encouraging results from a Phase 1 study of the company's drug Tivoxavir Marboxil in the treatment of H5N1 avian flu.
The study showed a single dose of the drug maintained plasma drug levels above the effective concentration, EC90, for over 23 days, indicating the potential for sustained efficacy with a one-time administration. No treatment-related adverse events were reported, according to a statement.
The company said plans were underway to initiate a Phase 2 study of the product in the first half of 2025.
https://www.msn.com/en-us/money/markets/traws-stock-rallies-24-on-avian-flu-drug-update/ar-BB1rfQwW
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.